Update from Autifony Therapeutics’ QUIET-1 tinnitus clinical trial

Headline data from QUIET-1 confirm lack of efficacy of AUT00063 in the treatment of people with mild-to-moderate tinnitus AUT00063 was safe and well tolerated Trial of AUT00063 in age-related hearing loss continuing London – UK – 28th April 2016 – Autifony, along with Innovate UK, sponsored a Phase IIa tinnitus clinical trial in the UK. Professor Jaydip Ray, ENT Surgeon at Sheffield Teaching Hospitals & Sheffield Children’s Hospital, was the national Coordinating Investigator for this clinical trial. Our lead academic collaborator was the University of Nottingham (Professor Deborah Hall). This “proof-of-concept” study explored the potential of Autifony’s lead Kv3 modulator, AUT00063, to reduce the symptoms in people with subjective tinnitus. Read more (283 kB)

The release as fetched from its publisher. autifony.com ↗